Cannabis use during pregnancy associated with negative effects on birth outcomes.
A study published December 12th, 2023, in the Journal of the American Medical Association looked at how cannabis consumed during pregnancy affected the outcomes of births (1). To establish the importance of the study, which was titled “Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function,” researchers cited the lack of knowledge about how cannabis affects pregnancy, plus the rise in cannabis use among individuals of reproductive age (1).
Researchers from several universities and one laboratory confirmed cannabis exposure during the pregnancies of 9257 participants though frozen urine samples collected during three study visits spaced throughout the trimesters, then analyzed birth outcomes including low birth weight, preterm birth, and stillborn (1). These three birth outcomes were combined into one primary outcome due to their connection to placental function, explained lead study author Torri Metz, obstetrician and associate professor at the University of Utah Health (2).
Of the 610 participants exposed to cannabis, 32.4% were exposed only during the first trimester, and 67.6% were exposed beyond the first trimester (1). Researchers found that the adverse birth outcomes were associated with 25.9% of the exposed group compared to 17.4% in the group that was not exposed (1).
“Looking at any adverse outcome, we saw that people who had stopped use within the first trimester didn’t actually have a statistically significant increased risk [vs.] those who had continued use,” Dr. Metz (3).
The analysis was adjusted for certain characteristics and behaviors, including nicotine use (1).
“In this multicenter cohort, maternal cannabis use ascertained by biological sampling was associated with adverse pregnancy outcomes related to placental dysfunction,” stated the abstract (1). “Cannabis use should be avoided during pregnancy to optimize maternal and neonatal outcomes,” researchers concluded in one of the key points of the study (1).
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.